Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Onabotulinumtoxin A (onabotA) has shown efficacy in chronic migraine (CM), with good tolerability and a low rate of adverse effects, most of them not severe. The aim of this study is to evaluate tolerability and adverse effects of onabotA in clinical practice and to analyze if there is a relationship between tolerability to treatment administration...
Alternative Titles
Full title
Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7041dd73690641efa3b1c377671da686
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7041dd73690641efa3b1c377671da686
Other Identifiers
ISSN
2072-6651
E-ISSN
2072-6651
DOI
10.3390/toxins14120850
